Bank Pictet & Cie Europe AG Increases Stock Position in Boston Scientific Corporation $BSX

Key Points

• Bank Pictet & Cie Europe AG has significantly increased its stake in Boston Scientific Corporation by 75.3%, owning a total of 164,654 shares worth approximately $17.7 million as of the last reporting period.
• Boston Scientific reported earnings per share (EPS) of $0.75 for the last quarter, exceeding analysts' expectations and showing a strong revenue increase of 22.8% year-over-year.
• The company's stock has garnered a predominantly positive outlook from analysts, with an average rating of "Buy" and a price target around $118.17.

Bank Pictet & Cie Europe AG grew its holdings in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 75.3% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 164,654 shares of the medical equipment provider's stock after purchasing an additional 70,753 shares during the period. Bank Pictet & Cie Europe AG's holdings in Boston Scientific were worth $17,685,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Kingsman Wealth Management Inc. boosted its stake in shares of Boston Scientific by 24.7% in the second quarter. Kingsman Wealth Management Inc. now owns 33,433 shares of the medical equipment provider's stock valued at $3,591,000 after buying an additional 6,622 shares in the last quarter. Banque Pictet & Cie SA boosted its position in shares of Boston Scientific by 24.0% during the 2nd quarter. Banque Pictet & Cie SA now owns 340,579 shares of the medical equipment provider's stock worth $36,582,000 after purchasing an additional 66,004 shares in the last quarter. Dakota Wealth Management grew its stake in shares of Boston Scientific by 2.4% during the 2nd quarter. Dakota Wealth Management now owns 238,666 shares of the medical equipment provider's stock worth $25,635,000 after purchasing an additional 5,701 shares during the period. Perigon Wealth Management LLC increased its holdings in shares of Boston Scientific by 2.9% in the 2nd quarter. Perigon Wealth Management LLC now owns 13,926 shares of the medical equipment provider's stock valued at $1,496,000 after purchasing an additional 394 shares in the last quarter. Finally, McAdam LLC lifted its stake in shares of Boston Scientific by 5.4% in the second quarter. McAdam LLC now owns 2,404 shares of the medical equipment provider's stock valued at $258,000 after purchasing an additional 123 shares during the period. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Stock Down 0.0%

BSX opened at $98.03 on Friday. The firm has a market cap of $145.26 billion, a P/E ratio of 58.35, a PEG ratio of 2.36 and a beta of 0.65. The business's fifty day simple moving average is $103.90 and its 200 day simple moving average is $102.06. Boston Scientific Corporation has a 52 week low of $80.64 and a 52 week high of $109.50. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The company had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same period in the prior year, the firm earned $0.62 EPS. The firm's quarterly revenue was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, equities research analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Wall Street Analyst Weigh In

BSX has been the topic of several recent analyst reports. Jefferies Financial Group restated a "hold" rating on shares of Boston Scientific in a research report on Monday, July 21st. Robert W. Baird upped their price target on Boston Scientific from $117.00 to $123.00 and gave the stock an "outperform" rating in a report on Thursday, July 24th. Leerink Partnrs raised Boston Scientific to a "strong-buy" rating in a report on Monday, June 16th. Royal Bank Of Canada reiterated an "outperform" rating on shares of Boston Scientific in a research report on Thursday, July 24th. Finally, Needham & Company LLC restated a "buy" rating and issued a $121.00 price target on shares of Boston Scientific in a research report on Friday, September 19th. Three research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $118.17.

Insider Activity

In other news, Director Yoshiaki Fujimori sold 2,901 shares of the firm's stock in a transaction on Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total transaction of $310,377.99. Following the sale, the director owned 2,081 shares in the company, valued at $222,646.19. This trade represents a 58.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company's stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $105.43, for a total value of $5,271,500.00. Following the completion of the transaction, the executive vice president owned 178,342 shares of the company's stock, valued at $18,802,597.06. The trade was a 21.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 174,214 shares of company stock worth $18,397,457 in the last three months. 0.50% of the stock is owned by insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.